AARD
AARD
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
9
$23.87M
Insider Sales
1
$395K
Total Volume
$24.27M
16 transactions
Net Activity
+$23.48M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Strong buying bias: purchases represent 98% of total transaction value.
- •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale Insiders
$4987.90B total
Decheng Capital Global Life Sciences Fund Iv, L.P.
10%
$20.00M total
Cormorant Asset Management, LP
Former 10% Owner
$3.00M total
Sun Nelson
See Remarks
$647K total
Lee Tien-Li
CEO, 10%
$623K total
Quick Actions
AARD has an insider buy conviction of 98%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AARD (AARD) engaged in a total of 16 transactions reported via SEC Form 4 filings. Among these, 9 were open-market purchases and 1 were sales. The total volume of insider trading reached $24.27M.
The net insider activity for AARD shows a net buying bias of $23.48M. This activity represents a 98% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 3.92M shares valued at $4896.62B on Feb 14, 2025.
AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline
AARD - Aardvark Therapeutics Inc Stock Price and Quote
Why Is Aardvark Therapeutics Stock Trading Lower Today? - Aardvark Therapeutics (NASDAQ:AARD)
AARD Stock Price and Chart — NASDAQ:AARD
AARD Stock Slides As FDA Hold And Class Actions Mount
Aardvark Therapeutics (AARD) Stock Forum and Discussion
FAQs About AARD Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AARD.